• Article highlight
  • Article tables
  • Article images

Article History

Received : 14-03-2024

Accepted : 21-05-2024



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 230

PDF Downloaded: 91


Get Permission Basuri and Mohapatra: Critical review on analytical detection of first line and second line anti tubercular agent by various modern analytical method


Introduction

Tuberculosis (TB): Tuberculosis is a chronic granulomatous inflammatory infectious bacterial disease caused by Mycobacterium tuberculosis, which is most commonly affect the lungs.1

Epidemiology of TB

MTB has very ancient origins: it has lasted more than 70,000 years and actually infects almost 2 billion people worldwide in 2016, with about 10.4 million new cases of TB annually, about 33.33% of the world's population carries TB bacillus and is at risk of developing active disease.2

Approximately 10 million people worldwide are infected with MTB in 2018, 5.7 million men, 3.2 million women and 1.1 million girls, 1.6 million people expired from the disease currently available for treating TB, it remains incompetent, taking 6 to 9 months to cure the drug-susceptible variant and up to 2.5 years to cure MDR-TB.3

Classification of Tuberculosis (TB 4:)

Figure 1

Classification of tuberculosis

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/be566ca9-2d49-4185-8eae-e29ba2ee6cdfimage1.png

TB Pathogenesis

  1. TB is an infectious disease caused by M. Tuberculosis usually affects the lungs.4

  2. M. Tuberculosis is transmitted to atmosphere as airborne droplets, owing to runny noses of individuals with pulmonary tuberculosis (TB). Transmission done due to breathing of nuclei of these droplets which goes from the nasal cavities to upper respiratory tract, bronchi and then lastly goes to the alveoli of lungs.5

  3. First on M. Tuberculosis enters the alveoli and is swallowed by alveolar macrophages that cause a large ratio of inhaled tuberculosis bacilli to be destroyed.6

  4. The minor unchanged ratio reproduces inside the macrophages and is liberated upon death of the macrophages.7

  5. Approximately within 2 to 8 weeks,8 an immune defensive mechanism is activated which permits leukocytes to extinguish major proportion of the tubercle bacilli. The encapsulation by the leukocytes leads to the barrier formation around the tubercle bacilli developing a granuloma.7

  6. Once if it goes inside the hindrance shell, the tubercular bacilli are to be under control and it establish a stage of latent tuberculosis infection (LTBI). Persons will not give any indications of TB and infection are unable to spread.9

  7. On other hand, if the defensive mechanism is unable to keep the tubercular bacilli under control, then bacilli are quickly reproduced which leads to a development from latent tuberculosis infection to tuberculosis TB. 10

Diagnosis of TB 11, 12

  1. The medical history of patients

  2. Physical test

  3. M. Tuberculosis test

  4. Chest X-ray

  5. Bacteriologic examination

Treatment of tuberculosis:13, 14

Anti-tubercular agent: These are the medicines which are used for the tuberculosis treatment.

Drug profile of antitubercular agentsTable 1

Analytical Detection of Antitubercular Agents

First line antitubercular drugsTable 1

Second line antitubercular drugs:Table 2

New antitubercular drugsTable 4

Figure 2

Class of TB drugs

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/be566ca9-2d49-4185-8eae-e29ba2ee6cdfimage2.png

Table 1

Drug description of antitubercular agent

Sr. no.

Drug

Mechanism of action

1.

i)

Isoniazide 15, 16

Isoniazid interferes with the cell wall creation by inhibiting the synthesis of mycolic acid.

ii)

Pyrazinamide 17, 18

Pyrazinamide is a synthetic pyrazinoic acid amide derivative having bactericidal property. Pyrazinamide is mainly dynamic against gradually multiplying intracellular bacilli by an unfamiliar mechanism of action. Its bactericidal action is based on the bacterial pyrazinamidase, which eliminates the amide group to generate active pyrazinoic acid.

iii)

Ethambutol 19, 20, 21

Ethambutol prevent the transfer of mycolic acid in M. tuberculosis cell wall. Which leads to the weakening of cell wall resulting into cell death.

iv)

Rifampicin 22, 23

Rifampicin works by blocking DNA dependent RNA polymerase, which results in depletion of synthesis of RNA and death of cell.

2.

i)

Paraminosalicylic acid 24

Aminosalicylic acid works by two route. 1st- It inhibit folic acid production. Aminosalicylic acid bind to pteridine synthetase enzyme which is use for synthesis of folic acid. As bacteria is not able to use exterior source of folic acid leads to slow down the multiplication and growth of cell. 2nd - It may hinder the production of the cell wall constituent, mycobactin, which leads to dropping iron uptake by M. tuberculosis.

ii)

Thiacetazone 25

It is a bacteriostatic agent. Exact mechanism of thiacetazone is unknown. It can inhibit the synthesis of mycolic acid in mycobacterium tuberculosis leading to cell wall weakening which results in cell death.

iii)

Ethionamide 26

Ethionamide is a  derivative of nicotinamide. Actual mechanism of ethionamide is mysterious. It might prevent the creation of mycolic acid which leads to bacterial cell wall interruption and cell lysis.

iv)

Kanamycin 27

Kanamycin is an antibiotic class of the aminoglycoside. Aminoglycosides function by binding to the bacterial ribosomal subunit 30S, producing misinterpretation of t-RNA, Leads to bacteria is not able to synthesize protein which are essential for growth of cell.

v)

Amikacin 28

Amikacin fixes to bacterial 30S ribosomal subunits and affects with mRNA binding lead to inhibit protein synthesis which are necessary for its growth.

vi)

Cycloserine 29

Cycloserine blocks peptidoglycan formation, allows the cell wall to collapse and contributes to cell death.

vii)

Viomycin 30, 31

Viomycin restricts translocation which obstructs the synthesis of proteins, leading to death of bacterial cells.

3.

i)

Ofloxacin 32

Ofloxacin is a fluoroquinolone antibiotic. Ofloxacin inhibits bacterial topoisomerase II and topoisomerase IV mechanism, which are participating in duplication and repair of DNA, leads to cell death.

ii)

Ciprofloxacin 33

Ciprofloxacin is a synthetic broadspectrum fluoroquinolone antibiotic. Ciprofloxacin inhibits bacterial DNA gyrase mechanism, leads to obstruction of DNA replication, resulting in cell death.

iii)

Clarithromycin 34

Clarithromycin attach to 50S subunit of ribosome and hunder protein production in bacteria which is important for its growth.

iv)

Rifabutin 35

Rifabutin hinders bacterial DNA-dependent RNA polymerase, which inhibit transcription or RNA synthesis. Which leads to inhibition of protein synthesis which are essential for cell growth.

Diagram 1

Table 1+ Structure

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/be566ca9-2d49-4185-8eae-e29ba2ee6cdfimage3.png

Table 2

Analytical detection of first line antitubercular agents by HPLC

Sr. no

Method

Mobile phase

Stationary phase

Flow rate (ml/min)

Wavelength (nm)

Retention time (min)

i)

Isoniazide 36

Ethanol: water: 1%acetic acid (5.3:93.7:1, v/v/v)

C-18 column

1.5

265

2.28

Isoniazide 37

Water: methanol (85:15, v/v)

C-8 column (250 x 4.6mm,5m)

1.2

274

4.1

ii)

Pyrazinamide 38

0.02M Potassium dihydrogen phosphate (pH 2.6): acetonitrile (98:2, v/v)

C-18 column (25 cm × 4.6 mm, 5 µm)

1

268

8.4

iii)

Ethambutol 39

Methanol: water: glacial acetic acid (70:30:0.2, v/v/v)

C-18 column

1

210

29.26

iv)

Rifampicin 40

Methanol: acetonitrile: (0.075 M) monopotassium phosphate: (1.0 M) citric acid (28:30:38:4, v/v)

C-18 column (150 × 4.6 mm, 5m)

2

254

2.91

Table 3

Analytical detection of second line antitubercular agents by HPLC

i)

Paraminosalicylic acid 41

20 mM phosphate buffer, 20mM tetrabutylammoninum hydrogen sulphate and 16% (v/v) methanol adjusted to pH 6.8

C-18 column (50 mm × 4.6 mm, 5 µm)

1

233

2.783

ii)

Thiacetazone 42

Water: acetonitrile (92.5:7.5, v/v)

Internal surface reversed-phase (ISRP) mixed-functional phenyl column (Capcell Pak, 50x4.6 mm, 5 µm)

1

322

10.9

iii)

Ethionamide 43

Acetonitrile: phosphate buffer (75:25, v/v)

C-18 column (250×4.6mm, 5µm)

1.5

291

3.8

Ethionamide 44

Methanol: water (40:60, v/v)

C-18 column (250 × 4.6 mm, 5 µm) 

1

275

5.467

iv)

Kanamycin 45

22 mM disodium 1,2-ethanedisulfonate and 5 mM sodium octanesulfonate in a water-acetonitrile mixture (80:20, v/v)

C-18 column (40 × 8 mm,10 µm)

1.5

Ex: 351 Em: 440

9

Kanamycin 46

Acetonitrile:0.1 M sodium acetate buffer (pH 5.0; 25:75, v/v)

C-18 column (250 x 4.6 mm, 5 µm)

2

330

19.5

v)

Amikacin 47

Acetonitrile:0.1 M sodium acetate buffer (pH 5.0; 25:75, v/v)

C-18 column (250x4.6 mm, 5 µm)

2

330

8.7

Amikacin 48

Methanol:acetonitrile: acetate buffer (75:20:05 v/v)

C-18 column (250 mm x 4.6 mm, 5 μm)

1

212

4.61

vi)

Cycloserine 49

20mM Sodium hydrogen phosphate: acetonitrile (95:05, v/v)

Agilent Zorbax SB phenyl column (250 × 4.6 mm, 5 µm)

1

335

L- 10.4 D- 11.8

Cycloserine 50

10 mM Phosphate buffer: acetonitrile (90:10, v/v)

Atlantis T3, (150 × 4.6 mm, 3 µm)

0.4

240

5.1

Table 4

Analytical detection of new antitubercular agents by HPLC

i)

Ofloxacin 51

Acetonitrile: Buffer (35:65, v/v)

C-8 column (250 cm × 4.6 mm, 5 µm)

1.5

315

10

Ofloxacin 52

Triethylamine: acetonitrile :0.3% o-phosphoric acid ((0.02:20:80, v/v/v)

C-18 column (250 × 4.6 mm,5 µm)

1

290

6.15

Ofloxacin 53

0.03M Potassium dihydrogen phosphate: methanol (30:70, v/v)

C-18 column (150 × 4 mm,4 µm)

1

294

5.17

ii)

Ciprofloxacin 54

Phospahte buffer (2.7 pH): Acetonitrile (77:23, v/v)

C-18 column (250 x 4.6 mm, 5 μm)

1.5

277

3.26

Ciprofloxacin 55

2% Acetic acid: acetonitrile (84:16, v/v)

C-18 column (150 × 4.6 mm, 5 µm)

1

280

6.5

Ciprofloxacin 56

5% Acetic acid: acetonitrile: methanol (90:5:5, v/v/v)

C-18 column (150 × 6 mm, 5 µm)

1

280

12

Ciprofloxacin 57

Water: acetonitrile: triethylamine (80:20:0.3, v/v/v)

C-18 column (125 x 4 mm,5 µm)

1

279

2.4

C

Ciprofloxacin 58

0.025M Orthophosphoric acid (3 pH): methanol (60:40, v/v)

C-18 column (125x4mm, 5µm)

2

278

1.75

Ciprofloxacin 59

0.1M Potassium dihydrogen phosphate: acetonitrile (80:20, v/v)

C-18 column (250 mm × 4.6 mm, 10)

1.5

276

5.15

iii)

Clarithromycin60

Acetonitrile: methanol:0.04 M phosphate buffer (pH 6.9) (52:9:39, v/v)

Perkin-Elmer Spheri-5 cyano column (100 × 4.6 mm, 5 µm)

1

ECD

9.2

Clarithromycin 61

0.05M Phosphate buffer (3.2 pH): acetonitrile (50:50, v/v)

C-18 column (250 × 4.6 mm,5 mm)

1

205

2.21

Clarithromycin 62

Acetonitrile: methanol: potassium dihydrogen phosphate buffer (7.5 pH) (40:6:54, v/v)

C-8 column (125 × 4.0 mm)

1.5

Amperometric detector

4.8

Clarithromycin 63

Acetonitrile: formic acid: water: trifluoroacetic acid (70:15:14.9:0.1, v/v)

C-18 column (250x4.6 mm, 5 μm)

1

ELSD

4.7

Clarithromycin 64

Acetonitrile: phosphate buffer (11 pH) (60:40, v/v)

Asahipak Shodex ODP-50 4E column (250 mm × 4.6 mm, 5 μm)

1

210

6.46

Clarithromycin 65

Acetonitrile: 0.035 M potassium dihydrogen phosphate (pH 4.4) (55: 45, v/v)

C-18 column (150× 4.6 mm,5 µm

0.6

210

4.1

iv)

Rifabutin 66

50mM Phospahte buffer (4.2 pH): acetonitrile (53:47, v/v)

C-18 column (250 x 4.6mm,5m)

1.2

265

8.5

Rifabutin 67

Methanol: Water (75:25, v/v)

C-8 column (250 × 4.6 mm,5 µm)

1

240

5.5

Rifabutin 68

Acetonitrile + Methanol (1:1): Water (75:25, v/v)

C-18 column (250 x 4.6mm,5m)

1

242

5.3

Conclusion

Tuberculosis is a prolonged bacterial infection caused by Mycobacterium tuberculosis, characterised by the development of granulomas in infected tissues and by hypersensitivity mediated by the cells. About 10 million people worldwide became contaminated with MTB in 2018, 5.7 million men, 3.2 million women and 1.1 million kids, 1.6 million die from illness. This article includes epidemiology, classification, pathogenesis, diagnosis and treatment of Tuberculosis. It includes the drug profile of antitubercular agents such as isoniazid, pyrazinamide, ethambutol, rifampicin, paraminosalicylic acid, thiacetazone, ethiomnamide, kanamycin, amikacin. cycloserine, viomycin, morphazinamide and fewer new mwdicines include ofloxacin, ciprofloxacin, clarithromycin and rifabutin. It contains analytical detection method of antitubercular agents by HPLC. From the study we can conclude that there are various analytical detection methods are available. The current work contains compilation of the analytical detection method antitubercular agents by HPLC.

Source of Funding

None.

Conflict of Interest

None.

References

1 

S Shang S Siddiqui Y Bian J Zhao CR Wang Nonclassical MHC Ib-restricted CD8+ T cells recognize mycobacterium tuberculosis-derived protein antigens and contribute to protection against infection.PLoS pathogens2016126e1005688

2 

I Barberis N L Bragazzi L Galluzzo M Martini The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. Journal of preventive medicine and hygiene20175899

3 

World Health OrganizationWorld Health Organization. World malaria report2015

4 

K Floyd A Pantoja Financial resources required for tuberculosis control to achieve global targets set for 2015Bulletin of the World Health Organization20088656876

5 

A Kay P M Barry P Annambhotla C Greene M Cilnis P Chin-Hong N Arger L Mcnitt N Neidlinger N Shah S V Basavaraju Solid Organ Transplant-Transmitted Tuberculosis Linked to a Community Outbreak-CaliforniaMMWR. Morbidity and mortality weekly report201566801801

6 

N W Schluger The pathogenesis of tuberculosis: the first one hundred (and twenty-three) years. American journal of respiratory cell and molecular biology200532251257

7 

I Smith Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clinical microbiology reviews20031646396

8 

C A Haley Prevention of Tuberculosis: TB Screening, Diagnosis of Latent Tuberculosis Infection and Preventive Therapy. South-eastern National Tuberculosis Centre2013

9 

M Raviglione G Sulis Tuberculosis 2015: burden, challenges and strategy for control and elimination. Infectious disease reports20168

10 

P R Donald B J Marais C E Barry Age and the epidemiology and pathogenesis of tuberculosis. The Lancet201037518521856

11 

J E Golub S Bur W A Cronin S Gange N Baruch G W Comstock R E Chaisson Delayed tuberculosis diagnosis and tuberculosis transmission. The international journal of tuberculosis and lung disease2006102430

12 

A A Agyeman R Ofori-Asenso Tuberculosis-an overviewJournal of Public Health and Emergency201717

13 

J Radloff J Heyckendorf L Van Der Merwe Sanchez Carballo P Reiling N Richter E Lange C Kalsdorf B Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmette-Guérin VaccinationFrontiers in immunology2018917081708

14 

D Maher P Chaulet S Spinaci A Harries Treatment of tuberculosis: guidelines for national programmes1997177

15 

G J Alangaden B N Kreiswirth A Aouad M Khetarpal F R Igno S L Moghazeh E K Manavathu S A Lerner Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosisAntimicrobial agents and chemotherapy199842512951302

16 

G A Prosser L P De Carvalho Kinetic mechanism and inhibition of M ycobacterium tuberculosis d-alanine: d-alanine ligase by the antibiotic d-cycloserine. The FEBS journal2013280115066

17 

R Ciccone F Mariani A Cavone T Persichini G Venturini E Ongini V Colizzi M Colasanti Inhibitory effect of NO-releasing ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survivalAntimicrobial agents and chemotherapy2003172299302

18 

S Bosne-David V Barros S C Verde C Portugal H L David Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitorsJournal of Antimicrobial Chemotherapy2000463391396

19 

J Barluenga F Aznar A B García M P Cabal J J Palacios M A Menéndez New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters20061657175739

20 

K Johnsson D S King P G Schultz Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosisJournal of the American Chemical Society19951171750095019

21 

A Alahari X Trivelli Y Guérardel L G Dover G S Besra J C Sacchettini R C Reynolds G D Coxon L Kremer Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteriaPLoS One2007212

22 

A Ibrahim A Boutros J B Mcdougall Chemotherapy in a Cairo Chest Clinic: A preliminary report on the methods adopted in assessing the value of izoniazid, streptomycin and paraminosalicylic acid in 122 cases of pulmonary tuberculosisBritish Journal of Tuberculosis and Diseases of the Chest19554913849

23 

A Telenti P Imboden F Marchesi L Matter K Schopfer T Bodmer D Lowrie M J Colston S Cole Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. The Lancet199334164751

24 

G Acocella Clinical pharmacokinetics of rifampicinClinical pharmacokinetics197832108135

25 

R E Stanley G Blaha R L Grodzicki M D Strickler T A Steitz The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nature structural & molecular biology201017289289

26 

M Holm A Borg M Ehrenberg S Sanyal Molecular mechanism of viomycin inhibition of peptide elongation in bacteriaProceedings of the National Academy of Sciences201611397883

27 

Z Sun J Zhang X Zhang S Wang Y Zhang C Li Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolatesInternational journal of antimicrobial agents2008312115136

28 

G S Timmins V Deretic Mechanisms of action of isoniazid. Molecular microbiology20066212201227

29 

W W Weber D W Hein Clinical pharmacokinetics of isoniazid. Clinical pharmacokinetics197946401423

30 

Y Zhang D Mitchison The curious characteristics of pyrazinamide: a review. The international journal of tuberculosis and lung disease20037621

31 

W Shi X Zhang X Jiang H Yuan J S Lee C E Barry H Wang W Zhang Y Zhang Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosisScience2011333604916301632

32 

K Takayama J O Kilburn Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatisAntimicrobial agents and chemotherapy198933914931502

33 

V A Place J P Thomas Clinical pharmacology of ethambutol. American Review of Respiratory Disease196387901905

34 

S Sreevatsan K E Stockbauer X I Pan B N Kreiswirth S L Moghazeh W R Jacobs A Telenti J M Musser Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutationsAntimicrobial agents and chemotherapy1997418167781

35 

M Misumi N Tanaka Mechanism of inhibition of translocation by kanamycin and viomycin: a comparative study with fusidic acid. Biochemical and biophysical research communications19809264754

36 

J Liu J Sun W Zhang K Gao Z He HPLC determination of rifampicin and related compounds in pharmaceuticals using monolithic columnJournal of pharmaceutical and biomedical analysis2008462405414

37 

M Yan T Guo H Song Q Zhao Y Sui Determination of ethambutol hydrochloride in the combination tablets by precolumn derivatizationJournal of chromatographic science2007455269272

38 

J E Conte E Lin E Zurlinden High-performance liquid chromatographic determination of pyrazinamide in human plasma, bronchoalveolar lavage fluid, and alveolar cellsJournal of chromatographic science20003813340

39 

A K Hk Ramachandran G Simple and rapid method for simultaneous determination of isoniazid and acetyl isoniazid in urine by HPLCAsian Journal of Biomedical and Pharmaceutical Sciences20144344646

40 

C Nguyen Detection and Assay of Isoniazid Utilizing Isocratic High-Performance Liquid Chromatography

41 

A H Kumar A K Polisetty V Sudha A Vijayakumar G Ramachandran A selective and sensitive high performance liquid chromatography assay for the determination of cycloserine in human plasmaIndian Journal of Tuberculosis2018652118141

42 

E Vasbinder G Van Der Weken Y Vander Heyden W R Baeyens A Debunne J P Remon A M García-Campaña Quantitative determination of p-aminosalicylic acid and its degradation product m-aminophenol in pellets by ion-pair high-performance liquid chromatography applying the monolithic Chromolith Speedrod RP-18e columnBiomedical Chromatography20041815563

43 

D Song M G Wientjes J L Au Isocratic high-performance liquid chromatographic determination of thiacetazone by direct injection of plasma into an internal surface reversed-phase columnJournal of Chromatography B: Biomedical Sciences and Applications19976901-228994

44 

A U Madni M Ahmad N Akhtar M Ashraf Z A Shuja An improved HPLC method for the determination of ethionamide in serumJournal of the Chemical Society of Pakistan200830344952

45 

P Rahade S Sonawane A Bhalerao S Kshirsagar Development of a Validated RP-HPLC Method for Estimation of Ethionamide in Spiked Human Plasma with UV DetectionAsian Journal of Research in Pharmaceutical Science201664230234

46 

H Kubo Y Kobayashi T Nishikawa Rapid method for determination of kanamycin and dibekacin in serum by use of high-pressure liquid chromatography. Antimicrobial agents and chemotherapy198528521524

47 

M A Korany R S Haggag M A Ragab O A Elmallah Liquid chromatographic determination of amikacin sulphate after pre-column derivatizationJournal of chromatographic science2014528837884

48 

G S Teja B M Gurupadayya K V Sairam Analytical method development and validation of amikacin in pure and marketed formulation using HPLCINTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH201891043824388

49 

M A Korany R S Haggag M A Ragab O A Elmallah Liquid chromatographic determination of amikacin sulphate after pre-column derivatizationJournal of chromatographic science2014528837884

50 

K Karthikeyan G T Arularasu R Ramadhas K C Pillai Development and validation of indirect RP-HPLC method for enantiomeric purity determination of d-cycloserine drug substanceJournal of pharmaceutical and biomedical analysis2011544850854

51 

S A Ali C C Mmuo R O Abdulraheem S S Abdulkareem E T Alemika M A Sani M Ilyas High performance liquid chromatography (HPLC) Method development and validation indicating assay for ciprofloxacin hydrochlorideJournal of Applied Pharmaceutical Science201118239239

52 

S Gangishetty S Verma RP-HPLC method development and validation for simultaneous estimation of clarithromycin and paracetamol. ISRN Analytical Chemistry2013

53 

Z Tzouganaki M Koupparis Development and Validation of an HPLC Method for the Determination of the macrolide antibiotic Clarithromycin using Evaporative Light Scattering Detector in raw materials and Pharmaceutical Formulations

54 

B Habibi I Ghorbel-Abid R Lahsini Ben Hassen D C Trabelsi-Ayadi M Development and validation of a rapid HPLC method for multiresidue determination of erythromycin, clarithromycin, and azithromycin in aquaculture fish musclesActa Chromatographica2019312109121

55 

M M Alam M S Hossain S Bhadra U Kumar A S Rouf Development and validation of RP-HPLC method for quantitation of clarithromycin in matrix tablet dosage formDhaka University Journal of Pharmaceutical Sciences20173016975

56 

A H Kumar V Sudha G Ramachandran Simple and rapid liquid chromatography method for determination of rifabutin in plasmaSAARC Journal of Tuberculosis2012922635

57 

Y D Patil S K Banerjee RP-HPLC method for the estimation of Rifabutin in bulk dosage form. International journal for drug derivatives and research20124294297

58 

H Bartels R Bartels Determination of rifabutin by high-performance liquid chromatography using on-line concentration and column switchingJournal of Chromatography B: Biomedical Sciences and Applications19966862235275

59 

J Emami M Rezazadeh A simple and sensitive high-performance liquid chromatography method for determination of ciprofloxacin in bioavailability studies of conventional and gastroretentive prolonged-release formulationsAdvanced biomedical research20165

60 

S M Foroutan A Zarghi A Shafaati B Madadian F Abolfathi Rapid high-performance liquid chromatographic method for determination of clarithromycin in human plasma using amperometric detection: Application in pharmacokinetic and bioequivalence studiesIranian journal of pharmaceutical research: IJPR2013126565

61 

N M Kassab A K Singh E R Kedor-Hackmam M I Santoro Quantitative determination of ciprofloxacin and norfloxacin in pharmaceutical preparations by high performance liquid chromatography. Revista Brasileira de Ciências Farmacêuticas200541507520

62 

I Niopas A C Daftsios Determination of clarithromycin in human plasma by HPLC with electrochemical detection: validation and application in pharmacokinetic studyBiomedical Chromatography2001158507515

63 

M Kamberi K Tsutsumi T Kotegawa K Nakamura S Nakano Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection. Clinical chemistry19984412511256

64 

S S Wu C Y Chein Y H Wen Analysis of ciprofloxacin by a simple high-performance liquid chromatography methodJournal of chromatographic science2008466490495

65 

M Amini K Abdi M Darabi A Shafiee Determination of ofloxacin in plasma by HPLC with UV detectionApplied Sci20055916551655

66 

V Maslarska B Tsvetkova L Peikova S Bozhanov RP-HPLC Method for Simultaneous Determination of Metronidazole and Ofloxacin in Synthetic MixtureInCBU International Conference Proceedings20164900905

67 

S K Patel A A Smith S Amuthalakshmi V N Gandhi R Manavalan Analytical method development and validation of Ofloxacin eye drop by HPLCJ. Curr. Chem. Pharm. Sc2011115964

68 

J Vella F Busuttil N S Bartolo C Sammut V Ferrito A Serracino-Inglott L M Azzopardi G Laferla A simple HPLC-UV method for the determination of ciprofloxacin in human plasmaJournal of Chromatography B20159898085



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.